Yong-Mi Kim, MD, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, has been awarded a 3 year translational research program (TRP) grant from the Leukemia & Lymphoma Society to study a novel approach to eradicating minimal residual disease in patients with acute lymphoblastic leukemia (ALL).
ALL is the most common pediatric cancer. Forty years ago, only one in five children survived this disease. Today with the development of powerful chemotherapies, over 90 percent of patients can expect to be cured. Unfortunately, for those children who do not respond to therapy, the prognosis is grim. New approaches are needed for these children with relapsed ALL.
Instead of targeting only the leukemia cells, Kim plans to expand the target. "We know that leukemia cells can hide out in the bone marrow where certain other cells shield them from chemotherapy," says Kim who is also an associate professor of Pediatrics and Pathology at the Keck School of Medicine of the University of Southern California. "The focus of our research will be on those cells that harbor the leukemia cells." The surviving cancer cells have been shown to be the source of disease relapse.
Kim and her co-investigators have identified a molecule that shelters leukemia cells, an adhesion molecule called integrin alpha4. This molecule allows leukemia cells to remain in the bone marrow, sheltering them from the otherwise toxic effects of chemotherapy.
According to the researchers, there is no treatment currently available that targets this molecule for patients with leukemia. However, a novel inhibitor of integrin alpha4 is being studied for other applications.
"We will test the effects of this novel inhibitor of integrin alpha4 on residual leukemia cells, with the eventual goal of developing it for clinical use," said Kim.
Co-investigators on this study include Alan Wayne, MD, director of the Children's Center for Cancer and Blood Diseases at CHLA and professor Pediatrics at the Keck School of Medicine of USC, and Deepa Bhojwani, MD, director of the Leukemia and Lymphoma Program at CHLA and associate professor of Pediatrics at the Keck School of Medicine of USC. Other collaborators include Thomas Graeber, PhD, and Daniel Braas, PhD, both of UCLA.
###
About Children's Hospital Los Angeles
Children's Hospital Los Angeles has been named the best children's hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at http://researchlablog.org/.
Media Contact
Ellin Kavanagh
[email protected]
323-361-8505
@childrensLA
http://www.childrenshospitalla.org
